NOVA EYE MEDICAL LTD

Sýn reported a slight revenue increase in Q2 2025 to 5,357 million kr. and a net loss of 174 million kr., with an improved first-half cash flow thanks to reduced investments. The company is cutting costs, reducing headcount and pursuing strategic measures such as the joint venture "Sendafélagið" with Nova, which is expected to deliver annual savings and balance sheet relief. For 2025 Sýn forecasts an EBITDAAL of 4.0–4.2 billion kr. and stresses that the measures are intended to support a long-term return to profitability. » Więcej na de.investing.com

Nova Limited reported non-GAAP EPS of $2.20 for Q2 2025 (forecast $2.10) and record revenue of $220 million, both above expectations, after which the stock rose 4.89% in premarket trading. The company posted 40% year-over-year revenue growth, strong margins, and issued Q3 2025 guidance of $215–227 million in revenue and non-GAAP EPS of $2.20–2.22. CEO Gabby Weissman cited AI as a growth driver and emphasized the importance of the Gate-All-Around strategy; risks remain in supply chains, market saturation, and geopolitical tensions. » Więcej na de.investing.com

Vigil Labs, founded by Kole Lee, raised $5.7 million in a seed round led by Nova to develop a proprietary AI reasoning system and real‑time data infrastructure to augment human traders. The Palo Alto startup combines social, predictive market and traditional data to create a continuous prediction engine and aims to scale into a large AI-driven hedge fund. Founders and early team members include Kole Lee, CTO Calder White and CPO Daniel Nunes; investors include Lux Capital, Pantera Capital and prominent angel backers. » Więcej na forbes.com